Correlation and efficacy of <scp>TACE</scp> combined with lenvatinib plus <scp>PD</scp>‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features

Abstract

Compared with TACE+LEN, the triple combination treatment of TACE+LEN + PD-1 has more promising clinical outcomes and acceptable safety in patients with HCC and PVTT. Child-Pugh grade, PVTT classification, and IL-6, IL-17, IFN-α, and VEGF levels are independent prognostic factors for survival time.